For the complete report, get in touch with us at : info@netscribes.com Anti-infective pharmaceuticals market in India is the largest contributor to domestic pharmaceutical sales, contributing around 18%. Since India has a huge patient pool, the Indian market is characterized by a huge demand for anti-infective drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the patient population, increasing number of vaccine approvals, increase in health insurances and introduction of newer and better drugs is helping the market to grow. The Indian Government, on its part, has introduced some control programmes, undertaken various Private Partnership Projects (PPP) and has taken initiatives to reduce drug prices. The market is expected to exhibit steady growth over the next few years. The report begins with the introduction section which offers a brief classification of the anti infectives market. It then moves to the market overview section which provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth. An analysis of the drivers explains the factors for growth of the industry including increasing patient population, increasing vaccine approvals, increase in health insurances and introduction of newer and better drugs. The key challenges include pricing pressure and logistic problems in the vaccine market. The government initiatives section gives a brief description of the different control programmes undertaken by the Government. It also analyses the efforts to reduce drug prices, changes in the customs duty structure and the various PPP projects undertaken by the Government. A brief overview of the drug regulations and patents is presented in the next section. It focuses the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. The section also provides a list of important patent approvals for anti infective drugs. The competition section gives overview of pharmaceutical companies in the country operating in the anti diabetic pharmaceutical and insulin segments. Thereafter, the report highlights the features of the major players operating in the market in detail. It includes elaborate profile of the major players in the market along with their financial analysis. Porters Five Forces Analysis has been incorporated for a brief but effective understanding of the market scenario. It also incorporates the recent developments in the Anti Infective Pharmaceutical industry. The strategic recommendations section focuses on some effective strategic decisions which can be taken up by companies to increase their market shares. Foray into the production of adult vaccines and improvement in the logistics of the vaccine market will help the companies increase their customer base.

1. Anti‐Infective Pharmaceuticals Market ‐ India
April 2012

2. Executive Summary
 Global anti‐infective pharmaceuticals market was valued at INR xx.x units while in India it was
valued at INR yy.y units in 20‐‐
 The market is expected to grow at a CAGR of m% from 20‐‐ to 20‐‐ globally and at n% CAGR in
Market India
 Anti infectives are the largest contributor to India’s domestic sales in 20‐‐, contributing around
z%
Drivers and
Drivers:
 Increasing patient population
LE
Challenges:
 Pricing pressure
Challenges
M
 Increase in health insurancesP
 Increasing number of vaccine approvals  Logistic problems in the vaccine market
Drug Regulation
and Patents
 Introduction of new drugs
 Phases of clinical trial
S A
 Approval and licensing of drugs
 Patents
 Highly fragmented market with large number of players
Competition  Major foreign players in the market include Gilead inc, Abbott, Glaxosmithkline etc
 Major domestic companies include Ranbaxy, Cipla, Dr. Reddy’s, Sun Pharmaceuticals, Panacea
Biotech, Torrent Pharmaceuticals among others
Strategic  Foray into the adult vaccine market
Recommendations  Strategic partnerships with Governmental and private bodies
ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 2

3. •Introduction
•Market Overview
LE
•Drivers & Challenges
M
•Government InitiativesP
S A
•Market Value Chain, Regulation and
Patents
•Competition
•Strategic Recommendation
•Appendix
ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 3

4. Indian anti‐infectives market is expected to witness an
enormous growth over the coming years
Indian Market – Overview Market Size and Growth
• Anti‐infectives belong to the acute segment which INR units
makes up around z% of the total pharmaceutical 200
industry x% x6
150 x5
x4
LE
 Anti‐infectives are the largest contributor to domestic x3
pharmaceuticals sales, contributing around y% x2
100 x1
P
 Cephalosporins, penicillins and quinolones are key drug
classes among anti‐infectives, with a share of around z% of 50
M
the country’s anti‐infectives market 0
• Presently the market has a size of INR X bn, and is
A
20‐‐ 20‐‐ 20‐‐e 20‐‐e 20‐‐e 20‐‐e
expected to grow at a CAGR of x% from 20‐‐‐‐‐
• In 20‐‐ GSK’s Augmentin was the highest selling drug
with sales of INR Y bn S
 Zifi, Taxim ,Monocef, Mox, Taxim‐O , Zinacef and Gerimac
Top pharmaceutical segments – 20‐‐
anti‐infectives
0 2 4 6 8 10 12 14 16 18
%
y1
were the other top selling drugs
CVS y2
• India has emerged as one of the leading vaccine gastro y3
manufacturer in recent times, producing z% of the CNS y4
global health vaccines respiratory y5
 Pentaxim, Varivax and Prevenar were the top selling diabetes y6
vaccines in 20‐‐ pain y7
oncology y8
Source:
ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 4

5. Drivers & Challenges – Summary
LE
Drivers
MP Challenges
Increasing patient population
Increasing number of vaccine
approvals
S A Pricing pressure
Logistic problems in the vaccine
market
Increase in health insurances
Introduction of new drugs
ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 5

6. Government Initiatives – Summary
Changes in tax structure Control programmes
Government
Initiatives
LE
PPP Projects Reduction in drug prices
MP
S A
ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 6

7. Pharmaceutical value chains involve the entire process
from drug discovery to drug marketing
A pharmaceutical value chain is a chain of activities which are involved in producing drugs, starting with raw
materials and ending with the delivered product
Sales
Drug Drug
Manufacturing Distribution and
Discovery Development
Marketing
Drug development Distribution of a
Pharmaceutical
LE
Drug discovery is the process of Drug manufactured drug
marketing,
involves the bringing a new manufacturing are involves the
sometimes called
P
identification, drug to the market the systems process by which
medico marketing,
synthesis and once a lead required for the the drug is
is the process of
M
screening of compound has quality control supplied to the
advertising or
A
chemicals for been identified covering the stockists,
otherwise
therapeutic through the manufacture and substockists,
S
promoting the sale
efficacy process of drug testing of drugs hospitals and retail
of drugs
discovery pharmacy shops
Source:
ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 7

8. Public: Domestic Company – A Company (1/3)
Company Information Offices and Centres – India
X Road
Corporate Address
Bangalore
Tel No. +91 xx xxxxx xxxxx
Fax No.
Website
+91 xx xxxxx xxxxx
www.ppp.com
LE
P
Year of Incorporation 19‐‐
M
Ticker Symbol xxxxxx
A
Stock Exchange NNN
Products and Services
Category Products/Services
S City A
Head Office
CVD, CNS, respiratory, dermatology, Key People
Pharmaceutical orthopedics, nutritional, urology, anti‐
infectives Name Designation
Infectious diseases, metabolic diseases, Person M Founder
Molecule
inflammatory/respiratory diseases, and Person N CFO
Development
oncology
Person O Head
Person Q President
Source:
ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 8

9. Public: Domestic Company – A Company (2/3)
Financial Snapshot Key Ratios
Revenue Profit Particulars y‐o‐y change 20‐‐ 20‐‐ 20‐‐ 20‐‐
INR mn Revenue INR mn Profitability Ratios
q r Profit / Loss
10,000 p Operating Margin
s Net Margin
n Profit Before Tax Margin
LE
5,000
m n o p 0 Return on Equity
t Return on Capital Employed
P
0 ‐m Return on Working Capital
20‐‐ 20‐‐ 20‐‐ 20‐‐ Return on Assets
M
Financial Summary Return on Fixed Assets
Cost Ratios
• The company incurred a net loss of INR xx mn in FY 20‐‐, as
compared to net profit of INR yy mn in FY 20‐‐
• The company reported total income of INR xx bn in FY 20‐‐,
registering an increase of yy per cent over FY 20‐‐
• The company earned an operating margin of x per cent in FY 20‐‐ a
S A Operating costs (% of Sales)
Administration costs (% of
Sales)
Interest costs (% of Sales)
Liquidity Ratios
Current Ratio
decrease of y percentage points over FY 20‐‐
Cash Ratio
• The company reported debt to equity ratio of x in FY 20‐‐, an Leverage Ratios
increase of y per cent over FY 20‐‐ Debt to Equity Ratio
Debt to Capital Ratio
Financial Summary
Interest Coverage Ratio
Indicators Present Value Efficiency Ratios
Market Capitalization (INR) X units Fixed Asset Turnover
Total Enterprise Value (INR) Y units Asset Turnover
Current Asset Turnover
EPS (INR) Z units
Working Capital Turnover
PE Ratio (Absolute) A Capital Employed Turnover
Source: Improved Decline
ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 9

10. Public: Domestic Company – A Company (3/3)
Key Business Segments Key Geographic Segments
m n o x y z
x
x
LE
x x
x
x x y
x y y
y
z y z y z
y
z
y
MP z
20‐‐
z
20‐‐
z
20‐‐
z
20‐‐
A
20‐‐ 20‐‐ 20‐‐ 20‐‐
Key Recent Developments
Overview
Description S News
• Company A is an integrated research based company that produces a wide range of generic medicines
• Serves customers in over 100 countries with manufacturing facilities in several countries
Anti Infectives
• Anti infective drugs and injectibles include Product 1 and Product 2
Pharmaceuticals
• Is making consistent effort for continual improvement in rural areas with respect to accessibility of
Key Initiatives medicines
Source:
ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 10

11. Thank you for the attention
The Anti‐Diabetic Pharmaceuticals Market – India report is part of Netscribes’ Healthcare
Industry Series.
For more detailed information or customized research requirements please contact:
Contact Number: +91 33 4064 6215
E‐Mail: sales@netscribes.com
Netscribes (India) Pvt. Ltd. is dedicated to disseminating information and providing quick insights on “hot” industries in India and other
emerging markets. Track our new releases and major updates in these industries on
About Netscribes
Netscribes is a knowledge‐consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment &
business research, business & corporate intelligence, content‐management services, and knowledge‐software services. At its core lies a true
value proposition that draws upon a vast knowledge base. Netscribes is a one‐stop shop designed to fulfil clients’ profitability and growth
objectives.
Disclaimer: This report is published for general information only. Although high standards have been used the preparation, Netscribes (India)
Pvt. Ltd. or “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the sole property of
Netscribes (India) Pvt. Ltd. and prior permission is required for guidelines on reproduction.
ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 11